| 000 | 01815 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250517150704.0 | ||
| 264 | 0 | _c20171211 | |
| 008 | 201712s 0 0 eng d | ||
| 022 | _a1097-4652 | ||
| 024 | 7 |
_a10.1002/jcp.25952 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBahrami, Afsane | |
| 245 | 0 | 0 |
_aThe therapeutic potential of targeting the BRAF mutation in patients with colorectal cancer. _h[electronic resource] |
| 260 |
_bJournal of cellular physiology _cMar 2018 |
||
| 300 |
_a2162-2169 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAmino Acid Substitution _xgenetics |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 |
_aCarbamates _xtherapeutic use |
| 650 | 0 | 4 |
_aCinnamates _xtherapeutic use |
| 650 | 0 | 4 |
_aColorectal Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aDrug Resistance, Neoplasm _xgenetics |
| 650 | 0 | 4 |
_aErbB Receptors _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aExtracellular Signal-Regulated MAP Kinases _xmetabolism |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImidazoles _xtherapeutic use |
| 650 | 0 | 4 |
_aIndoles _xtherapeutic use |
| 650 | 0 | 4 |
_aMAP Kinase Kinase Kinases _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aOximes _xtherapeutic use |
| 650 | 0 | 4 | _aPhosphoinositide-3 Kinase Inhibitors |
| 650 | 0 | 4 |
_aPiperazines _xtherapeutic use |
| 650 | 0 | 4 |
_aProto-Oncogene Proteins B-raf _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aSulfonamides _xtherapeutic use |
| 650 | 0 | 4 | _aVemurafenib |
| 700 | 1 | _aHesari, AmirReza | |
| 700 | 1 | _aKhazaei, Majid | |
| 700 | 1 | _aHassanian, Seyed Mahdi | |
| 700 | 1 | _aFerns, Gordon A | |
| 700 | 1 | _aAvan, Amir | |
| 773 | 0 |
_tJournal of cellular physiology _gvol. 233 _gno. 3 _gp. 2162-2169 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/jcp.25952 _zAvailable from publisher's website |
| 999 |
_c27078782 _d27078782 |
||